Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Maartje W. Rohaan(The Netherlands Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center)
Cited by 517
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799